Gender differences in right ventricular function in patients with non-ischaemic cardiomyopathy by M. Martínez-Sellés et al.
Original article
Published online: 7 October 2015
© The Author(s) 2015. This article is published with open access at Springerlink.com
Gender differences in right ventricular function  
in patients with non-ischaemic cardiomyopathy
M. Martínez-Sellés · E. Pérez-David · R. Yotti ·  
J. Jiménez-Borreguero · G. Loughlin · L. Gallego ·  
A. Ayesta · M.J. Olivera · J. Bermejo · F. Fernández-Avilés
Neth Heart J (2015) 23:578–584
DOI 10.1007/s12471-015-0753-y
(39 ± 3 %) p = 0.035. Only one woman (8 %) had severe 
RV systolic dysfunction (RVEF < 35 %) compared with 6 
men (50 %) p < 0.001. In patients with moderate and mild 
LV dysfunction , the mean RVEF was normal in both men 
and women. In the 14 healthy volunteers, the lowest value 
of RVEF was 48 % and mean RVEF was normal in women 
(56 ± 2 %) and in men (51 ±  1 %), p = 0.08.
Conclusions In patients with dilated cardiomyopathy, RV 
systolic dysfunction is found mainly in male patients with 
severe LV systolic dysfunction.
Keywords Sex · Gender · Right ventricle · Dilated 
cardiomyopathy · Heart failure
Women with systolic heart failure have a better progno-
sis than men [1], particularly in the case of non-ischaemic 
dilated cardiomyopathy [1, 2], but the causes of this differ-
ence remain unknown [3]. Right ventricular (RV) dysfunc-
tion has been associated with impaired exercise capacity 
and higher mortality in patients with systolic heart failure 
[3–11], and gender-related differences in RV function in 
healthy subjects have been suggested [12–14], with higher 
values of right ventricular ejection fraction (RVEF) in 
females compared with males [5, 12, 14] in spite of a simi-
lar left ventricular ejection fraction (LVEF) [14]. Also, it 
has been previously reported that women with systolic heart 
failure less often present with RV dysfunction than men [15, 
16]. The superior RV function observed in females could 
explain, at least in part, why women with non-ischaemic 
dilated cardiomyopathy have a better prognosis than men.
In spite of the importance of the right ventricle, knowl-
edge regarding this chamber is relatively scarce [17]. 
This is due, in part, to the complex geometry of the right 
ventricle, which renders precise measurement of RVEF 
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dimensions and function technically challenging. The exis-
tence of RV diastolic dysfunction has been demonstrated 
in patients with dilated cardiomyopathy and may have a 
potential role in patient outcomes [18]. Cardiac magnetic 
resonance imaging (MRI) can accurately measure RV vol-
umes and function and has become the gold standard for 
the evaluation of the right ventricle, and MRI-derived RV 
volumes correlate strongly with prognosis in patients with 
systolic heart failure [19].
Our main aim was to evaluate sex-related differences in 
RV function, measured with cardiac MRI, in patients with 
dilated cardiomyopathy and severe left ventricular (LV) 
systolic dysfunction and no relevant comorbidity. We also 
assessed sex-related differences in RV function in patients 
with dilated cardiomyopathy without severe LV systolic 
dysfunction. Finally MRI was also performed in healthy 
volunteers, in order to evaluate gender-related RV differ-
ences in subjects with no previous cardiac disease.
Methods
We designed a prospective study, performed in two univer-
sity hospitals in Madrid, Spain.
Patients
We enrolled patients with chronic heart failure in whom sig-
nificant coronary artery disease had been excluded by coro-
nary angiography, who had been clinically stable for at least 
a month prior to inclusion, and who presented LV systolic 
dysfunction with LVEF < 30 % measured with echocardiog-
raphy in the previous 4 months.
Exclusion criteria included all relevant comorbidities: 
diabetes, clinical criteria for chronic obstructive pulmonary 
disease or previous spirometry with significantly impaired 
pulmonary function, history of thromboembolic disease, 
creatinine > 2 mg/dL, and any systemic disease with a life 
expectancy < 2 years; hospitalisation for heart failure in the 
last month; patients with an implanted device that contrain-
dicated MRI (pacemaker, defibrillator, or other); women of 
childbearing age in whom pregnancy could not be excluded; 
patients with claustrophobia; patients with significant val-
vular stenosis or severe aortic regurgitation; patients with 
congenital heart disease and those who had undergone pre-
vious heart transplant.
The study complies with the Declaration of Helsinki and 
was approved by the Institutional Review Board of Hospital 
Universitario Gregorio Marañón, Madrid, Spain. All sub-
jects provided written informed consent prior to inclusion.
Clinical evaluation, ECG, non-imaging tests, and treatment
A thorough clinical evaluation was performed in all patients. 
Twelve-lead ECG was also performed. Blood tests included 
a complete blood count, chemistry and natriuretic peptide 
assessment. Cardiopulmonary stress testing (including mea-
surement of respiratory gas exchange) and spirometry were 
recommended in all patients unless there was a reason not to 
do so (a number of patients were unable to perform a stress 
test). A normal spirometry was defined as FVC and FEV1 
greater than 80 % of predicted values as well as FEV1/FVC 
greater than 70 % of the predicted value. Each patient’s drug 
regime was recorded.
LVEF and RVEF groups
We divided patients with dilated cardiomyopathy into three 
different groups according to LVEF measured with MRI: 
severe (< 25 %), moderate (25–34 %), and mild (35–50 %) 
LV systolic dysfunction. Regarding RV function we con-
sidered three groups: severe RV systolic dysfunction 
(RVEF < 35 %), moderate RV systolic dysfunction (RVEF 
35–44 %), and normal RV systolic function (RVEF > 44 %).
Healthy volunteers
MRI was performed in 14 healthy volunteers with no previ-
ous history of heart disease.
Imaging
Patients underwent contrast-enhanced MRI as described in 
the Appendix.
Statistical analysis
Quantitative variables are reported as mean ± SD, while 
qualitative variables are reported as numbers and percent-
ages. Continuous variables were compared using Student’s 
t-test, while categorical variables were compared using the 
chi-square test, or Fisher’s exact test where appropriate. All 
statistical analyses were performed using SPSS software 
(V16, SPSS, Chicago, Ill, USA). All p values are two-tailed.
Results
Baseline characteristics and treatment
We enrolled 71 patients, 38 men (53.5 %) and 33 women. 
Mean age was 60.9 ± 12.2 years. Two patients presented 
atrial fibrillation (2.8 %), the rest were in sinus rhythm. 
Baseline clinical characteristics were similar in males and 
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carvedilol (65 patients, mean daily dose 32.5 ± 18.8 mg). 
Ivabradine was not used in any patients. Same-day echocar-
diography showed severe mitral regurgitation in 6 patients 
(10.0 %) and moderate mitral regurgitation in 23 patients 
(38.3 %). Moderate aortic regurgitation was present in 4 
patients (6.7 %) and moderate tricuspid regurgitation in 3 
(5.0 %). There were no relevant differences regarding valve 
regurgitation between men and women (data not shown).
RVEF according to LVEF
A total of 24 patients (12 women) presented severe, 32 
moderate (13 women) and 15 mild (8 women) LV systolic 
dysfunction. Amongst patients with severe LV systolic dys-
function, women presented a higher mean RVEF (52 ± 4 % 
vs. 39 ± 4 %, p = 0.035) (Fig. 1); moreover, only one woman 
(8.3 %) had severe right systolic dysfunction compared with 
6 men (50.0 %), p < 0.001 (Fig. 2). In patients with moderate 
and mild LV dysfunction mean RVEF was normal in both 
men and women (Fig. 1).
We enrolled 14 healthy volunteers (mean age 45.2 ±  7.3 
years, 7 men). The lowest value of RVEF was 48 % and 
mean RVEF was normal in women (56.1 ± 2.3) and in men 
(51.1 ± 1.1), p = 0.08.
Other MRI parameters
Late enhancement was assessed after injection of gadodi-
amide in 65 patients (34 men). Despite the absence of sig-
nificant coronary artery disease in coronary angiography, 
subendocardial late enhancement was present in 5 men 
(14.7 %) and no women, p < 0.01. No significant differ-
ences were found in average pulmonary artery flow veloc-
ity between female and male patients, or between healthy 
men and women (Table 3). However, average pulmonary 
artery flow velocity was significantly lower in patients com-
pared with healthy volunteers (10.3 ± 3.2 versus 15.3 ± 3.4, 
p < 0.001). A significant correlation existed between pulmo-
nary artery flow velocity and RVEF (r = 0.35 p = 0.003).
females with the only exception being a higher prevalence of 
tobacco and alcohol consumption in males (Table 1). Labo-
ratory and functional test results revealed that men presented 
higher levels of haemoglobin as well as higher white blood 
cell counts than women, and performed better in cardiopul-
monary stress testing (Table 1). Treatment was similar in 
men and women (Table 2), three patients were not receiving 
beta blockers due to bradycardia (2 patients) and hypothy-
roidism, the rest were receiving bisoprolol (3 patients) and 
Table 1 Clinical characteristics and diagnostic test results in males 
and females.
Men (n = 38) Women (n = 33) P value
Variables (mean ± SD)
Age (years) 60.3 ± 13.2 61.5 ± 11.4 0.70
Weight (Kg) 76.2 ± 10.6 70.6 ± 22.9 0.18
Height (cm) 170.3 ± 7.9 155.0 ± 13.6 < 0.001
Body mass index 26.2 ± 2.6 27.6 ± 5.6 0.17
Systolic BP (mmHg) 121 ± 23 121 ± 21 0.99
Heart rate (bpm) 74 ± 14 72 ± 10 0.62
Years from DCM 
diagnosis
2.7 ± 3.5 2.1 ± 2.7 0.44
Variables N(%)
Tobacco 26 (68.4) 11 (33.3) 0.004




Previous HF admissions 32 (84.2) 24 (72.7) 0.25
Hypertension 14 (36.8) 13 (39.4) 0.83
Hyperlipaemia 13 (34.2) 14 (42.4) 0.49
ECG
QRS duration (mean ±  
SD)
120 ± 34 122 ± 29 0.71
LBBB N (%) 15 (39.5) 17 (51.5) 0.32
Blood tests (mean ± 
SD)
Hemoglobin g/dL 14.3 ± 1.4 13.3 ± 1.2 0.002
Leukocyte count/mL 8058 ± 1862 6761 ± 1996 0.008
BNP pg/mL 196 ± 223 331 ± 373 0.12
NT-proBNP pg/mL 1808 ± 2536 1651 ± 2194 0.84
Stress test (mean ± 
SD)
METs 6.8 ± 2.0 5.1 ± 1.6 0.002
Peak O2 consumption 
ml/kg/min
23.9 ± 6.3 18.4 ± 4.7 0.001
Spirometry
FEV1/FVC (Mean ± 
SD)
73.8 ± 8.4 76.4 ± 6.6 0.19
Normal spirometry (%) 22 (62.9) 10 (35.7) 0.03
RVEF if normal 
spirometry
52.9 ± 13.1 52.7 ± 10.9 0.97
RVEF if abnormal 
spirometry
48.1 ± 11.5 59.8 ± 11.8 0.01
BP blood pressure, DCM dilated cardiomyopathy, HF heart failure, 
LBBB left bundle branch block, BNP B-type natriuretic peptide, 
NT-proBNP amino-terminal pro BNP, METs metabolic equivalents, 
FEV1 forced expiratory volume in 1 s, FVC forced vital capacity.
Table 2 Medical treatment in males and females.
Men (n = 38) Women (n = 33) P value
Variable N (%)
Beta blockers 36 (94.7) 32 (97.0) 0.65
ACEI 33 (86.8) 28 (84.2) 0.81
ARB 7 (18.4) 8 (24.2) 0.56
Digoxin 5 (13.2) 2 (6.1) 0.32
Aldosterone 
antagonists
18 (47.4) 12 (36.4) 0.93
Diuretics 14 (36.8) 12 (36.4) 0.97
Statins 12 (31.6) 8 (24.2) 0.50
ACEI angiotensin-converting-enzyme inhibitors, ARB angiotensin II 
receptor blocker.
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abnormal spirometry results, patients with normal flow-vol-
ume curves performed better during stress testing, 5.1 ±  1.9 
METs vs 6.8 ± 1.9 METs, p = 0.005 and had a higher peak 
oxygen consumption 18.5 ± 5.7 ml/kg vs 24.3 ± 5.7 ml/kg, 
p = 0.01. Patients with and without RV dysfunction had 
similar results in stress tests, 5.8 ± 2.3 METs vs 5.9 ± 1.9 
METs, p = 0.90; peak oxygen consumption 21.2 ± 6.0 ml/kg 
vs 20.8 ± 6.7 ml/kg, p = 0.84.
Discussion
In our cohort of dilated cardiomyopathy patients, RV dys-
function was found mainly in male patients with severe left 
systolic dysfunction, suggesting a degree of protection from 
RV dysfunction amongst women. Our data confirm that RV 
dysfunction is unusual in patients with dilated cardiomyop-
athy; also, as expected, RV systolic dysfunction was found 
almost exclusively in patients with a very low LVEF [16]. 
Spirometry and stress test
Spirometry was performed in 64 patients, revealing normal 
flow-volume curves in 32 (45.1 %), reduced mid expiratory 
flow in 14 (19.7 %), moderate obstruction in 7 (10.9 %), 
mild obstruction in 6 (8.5 %), and a mild restrictive pattern 
in 5 patients (7 %). The prevalence of a normal spirometry 
was similar in patients with or without previous tobacco use 
(47.1 % vs 55.2 %, p = 0.53). A normal spirometry was more 
often found in men than in women (Table 1). In patients with 
a normal spirometry, RVEF was similar in men and women; 
however in patients with an abnormal spirometry result 
RVEF was lower in men. Also, compared with patients with 
Table 3 Magnetic resonance imaging (MRI) results in males and fe-
males.
Patients Men (n = 38) Women (n = 33) P value
Variable (mean ± SD)
LV mass (g) 147.8 ± 48.1 121.5 ± 44.0 0.02
LVEF (%) 28.4 ± 10.1 28.9 ± 10.3 0.84
RVEF (%) 50.7 ± 12.7 55.4 ± 13.5 0.14
LVEDV (mL) 312.6± 107.5 267.9 ± 100.1 0.08
LVESV (mL) 231.6 ± 108.5 198.8 ± 97.6 0.19
RVEDV (mL) 157.9 ± 47.5 132.5 ± 46.7 0.03
RVESV (mL) 80.9 ± 43.3 65.2 ± 44.0 0.13
iLVEDV (mL/m2) 123.1 ± 58.8 115.8 ± 56.0 0.49
iLVESV (mL/m2) 231.6 ± 108.5 156.7 ± 56.6 0.60
iRVEDV (mL/m2) 83.4 ± 25.5 77.4 ± 25.6 0.32







Average PA flow 
velocity (cm/s)
10.5 ± 3.1 10.0 ± 3.4 0.57
MRI-estimated PVR 4.7 ± 2.0 4.6 ± 2.4 0.8
Volunteers Men (n = 7) Women (n = 7) P value
Variable (mean ± SD)
LV mass 85.6 ± 27.1 64.9 ± 11.0 0.08
LVEF 62.3 ± 5.3 60.6 ± 5.2 0.55
RVEF 51.1 ± 3.1 56.1 ± 6.0 0.07
Average PA flow 
velocity (cm/s)
15.8 ± 2.9 14.8 ± 4.3 0.6
MRI-estimated PVR 2.5 ± 0.8 1.7 ± 2.4 0.2
LV left ventricular, LVEF left ventricular ejection fraction, RVEF 
right ventricular ejection fraction, DCM dilated cardiomyopathy, 
LVEDV left ventricular end-diastolic volume, PA pulmonary artery, 
LVESV left ventricular end-systolic volume, RVEDV right ventricular 
end-diastolic volume, RVESV right ventricular end-systolic volume, 
i index, PVR pulmonary vascular resistance.
Fig. 1 Mean right ventricular ejection fraction (RVEF) according to 
left ventricular ejection fraction (LVEF) group in men and women. 
Data from 71 adults with stable dilated cardiomyopathy and 14 healthy 
volunteers.
 
Fig. 2 Right ventricular ejection fraction (RVEF) group according to 
left ventricular ejection fraction (LVEF) group in men and women. 
Data from 71 adults with stable dilated cardiomyopathy and 14 healthy 
volunteers.
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fact, an increase in RV afterload through the development of 
pulmonary arterial hypertension secondary to chronic pul-
monary venous hypertension has long been considered the 
main underlying mechanism of RV failure [5] and pulmonary 
wedge pressure is the strongest predictor of RV dysfunction 
[23]. Phase contrast MR imaging is useful for non-invasive 
detection of pulmonary arterial hypertension. In a recent 
study published by Sanz et al., average pulmonary artery 
flow velocity showed good correlation with pulmonary 
pressures [24]. However, in our study, lower pulmonary 
pressures do not seem to explain the better performance of 
the female right ventricle in patients with very low LVEF. In 
fact, although average pulmonary artery flow velocity was 
significantly higher in patients with dilated cardiomyopathy 
than in healthy volunteers, no significant differences existed 
in pulmonary artery flow velocity between men and women. 
Nonetheless, patients with previous lung disease were not 
included in our study and a normal spirometry was more 
frequently found in men than in women. Interestingly, sex-
related differences regarding RVEF were seen in patients 
with a pathological result in spirometry. Areas of ischaemic 
late enhancement were present in 5 men (only 2 of them 
had LVEF < 25 %) and no women; this small number is not 
enough to explain the differences regarding RVEF.
The underlying reasons for the superior performance of 
the female right ventricle in patients with dilated cardiomy-
opathy is currently unknown. Oestradiol levels have been 
associated with better RV systolic function [25]. Another 
hormone, relaxin, is secreted by the ovaries and the pla-
centa, with increased levels during pregnancy that medi-
ate some of the haemodynamic changes associated with 
gravidness. Serelaxin, recombinant human relaxin-2, has 
recently been found to improve the prognosis in patients 
with heart failure [26]. Finally, the presence of XY chromo-
some positive cardiomyocytes in the hearts of women who 
have had male offspring has been reported [27]. Although 
the implications of this important finding are still unclear, 
it cannot be ruled out that the heart undergoes some degree 
of rejuvenation during pregnancy, which would provide an 
advantage in the event that the subject were to later develop 
dilated cardiomyopathy.
Although not gender-related, an additional interesting 
finding was the correlation between spirometry results with 
functional capacity and peak oxygen consumption, sug-
gesting a possible role of spirometry in risk stratification 
of these patients. Of note, lung function variables obtained 
by spirometry are frequently impaired in patients with heart 
failure and correlate with all-cause mortality [28] and a 
restrictive pattern in spirometry predicts poor survival in 
chronic heart failure [29].
Several limitations of our study need to be considered. 
The present work is based in a relatively low number of 
highly selected patients with chronic dilated cardiomyopathy 
However, the main finding of our study is that, in this sub-
group of patients with severely depressed LV systolic func-
tion, most men also presented RV systolic dysfunction, 
whereas this finding was unusual in women.
Multiple studies in heart failure patients have consis-
tently found a survival benefit in females, which is more 
pronounced in non-ischaemic heart failure [17]. However, 
the underlying causes for this improved prognosis remain 
unknown [3]. The largest study questioning the role of the 
right ventricle in chronic systolic heart failure was per-
formed by Meyer et al. [5], using the Beta-Blocker Evalua-
tion of Survival Trial (BEST) dataset, with RVEF measured 
with gated-equilibrium radionuclide ventriculography. 
These authors found that, compared with patients with nor-
mal RVEF, there were fewer women amongst those with a 
lower RVEF. We have also previously suggested, in a study 
performed with echocardiography, that the prevalence of RV 
dysfunction in patients with systolic heart failure is lower in 
women than in men [15]. Low RVEF is a strong predictor 
of poor outcome in patients with systolic heart failure [4]. A 
recent meta-analysis has confirmed the significant associa-
tion between RV systolic dysfunction and overall mortality 
[20]. Thus, it is conceivable that the better performance of 
the right ventricle encountered in women with chronic sys-
tolic heart failure could, at least in part, explain their more 
favourable prognosis [1].
Assessment of the right ventricle with echocardiogra-
phy is problematic [21], as it depends on both an adequate 
acoustic window and, due to the crescent shape of the right 
ventricle, on making certain geometric assumptions for the 
calculation of ventricular volumes. Identifying an accurate 
and reliable echocardiographic parameter for the functional 
assessment of the right ventricle still remains a challenge 
[21] and, although gated-equilibrium radionuclide ventricu-
lography is an alternative, it also entails significant limita-
tions, most importantly a poor spatial resolution [22]. We 
designed our study with the intent of confirming the superior 
performance of the female right ventricle in chronic systolic 
heart failure providing the most comprehensive and accu-
rate assessment of RV dimensions and function available. 
In this sense, cardiac MRI has excellent spatial resolution, 
can accurately measure volumes and RVEF without relying 
on geometric assumptions and is, in short, the gold standard 
for the non-invasive evaluation of the right ventricle [19]. 
Also, to avoid the presence of confounding variables, we 
selected patients with chronic dilated cardiomyopathy, opti-
mal medical treatment, and no comorbidity.
Although biventricular involvement can be occasionally 
found in non-ischaemic dilated cardiomyopathy, by itself, 
intrinsic myocardial damage is usually not sufficient to lead 
to RV failure, and an additional stressor is often necessary to 
provoke it [19], mainly in the form of increased pulmonary 
artery pressures, itself a consequence of LV dysfunction. In 
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to LV apex, achieving full coverage of the left ventricle) and 
4-chamber, 2-chamber and 3-chamber views. Phase-contrast 
MR images perpendicular to the main pulmonary artery and 
aorta were acquired with a segmented fast gradient echo 
MR sequence, with velocity encoding perpendicular to the 
imaging plane and a predefined upper velocity limit of 100 
cm/sec for the main pulmonary artery and 150 cm/s for the 
aorta. If aliasing was noted, the velocity was progressively 
raised in 30-cm/sec steps until it disappeared. Late enhance-
ment imaging (3D inversion recovery turbo gradient echo 
sequence, prepulse delay optimised for maximal myocar-
dial signal suppression; repetition time 3.4 ms, echo time 
1.3 ms, spatial resolution 1.5 × 1.8 mm, 5-mm slice thick-
ness, inversion time 200-300 ms) was performed in patients 
with dilated cardiomyopathy 10 to 15 minutes after a total 
injection of 0.2 mmol/kg gadodiamide (Omniscan®, GE 
Healthcare). Late enhancement images were obtained in the 
same short and long axis views defined for cine imaging. 
An echocardiogram was performed in the same day in 60 
patients (84.5%).
Ce-MRI data analysis
MRI analysis was performed by an investigator (EPD) with 
10 years of experience in MRI, blinded to patient clinical 
data. Cine, phase contrast, and late enhancement images 
were reviewed and analysed off-line in DICOM format 
with specialised postprocessing software (QMass® MR 7.0, 
QFlow 5.0 MEDIS, the Netherlands). Left and right ventric-
ular end-diastolic and end-systolic volumes were assessed 
based on the Simpson’s rule and LVEF and RVEF were 
obtained. LV mass was calculated by substracting the endo-
cardial volume from the epicardial volume at end diastole 
and then multiplying by the tissue density (1.05 g/ml). Axial 
views were used for RV and short-axis views for LV mea-
surements. The following parameters were calculated from 
phase contrast images: peak velocity, average velocity, min-
imum and maximum areas of aorta and pulmonary artery. 
Pulmonary artery pulsatility (relative change in lumen area 
during the cardiac cycle) was calculated as: maxA – minA/
minA × 100. Late gadolinium-enhanced images were visu-
ally analysed to identify intramyocardial areas of enhance-
ment. Four patterns were defined: a) No enhancement; b) 
Subendocardial or transmural enhancement; c) Typical 
non-ischaemic dilated cardiomyopathy, i.e. longitudinal or 
patchy midwall enhancement, not corresponding to the ter-
ritory of a coronary artery and not subendocardial; d) Other 
atypical patterns not involving subendocardium. An area of 
enhancement was only deemed to be present if it was seen in 
a short axis view and a cross-cut long axis image.
and no comorbidity, thereby potentially limiting the appli-
cation of our findings to larger non-selected populations as 
well as the power to detect the influence of certain factors 
such as the previous number of pregnancies. Also, the low 
number of healthy volunteers clearly precludes establishing 
definitive conclusions. Indeed, we were unable to confirm 
certain previously described sex-related differences [13, 14, 
30], specifically a higher average RVEF in healthy females 
compared with males [14, 30]. Moreover, the concept of a 
normal right ventricle is unclear, as RV wall motion abnor-
malities have been recently described in healthy subjects 
[31]. Finally, left and right ventricular systolic volumes are 
correlated and both are used to calculate ejection fraction. 
However, to the best of our knowledge, no study to date 
has examined the association of gender with RV function in 
optimal conditions (MRI, a population with ‘pure’ dilated 
cardiomyopathy and no comorbidity).
Conclusions
In chronic stable dilated cardiomyopathy patients, RV sys-
tolic dysfunction is found mainly in male patients with 
severe LV systolic dysfunction; on the other hand, females 
with severe LV systolic dysfunction present a normal mean 
RVEF.
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Appendix
Patients underwent contrast-enhanced MRI (ce-MRI) 
with a 1.5-T scanner (Philips Intera®, Best, the Nether-
lands) equipped with a Nova gradient system (33 mT/m; 
160 mT/m/ms). A five-element dedicated cardiac coil 
was used. All images were obtained with ECG gating and 
breath-holding. The MRI study consisted of cine steady-
state free-precession imaging of left and right ventricular 
function (SENSE × 2, repetition time, 2.4 ms; echo time 
1.2 ms, FOV 360 mm (up to 390 mm in obese patients to 
avoid fold-over), 30 phases per cycle, 8-mm slice thickness 
without gap) in axial views (10 to 15 contiguous slices from 
pulmonary artery bifurcation to inferior vena cava), short 
axis views (10 to 14 contiguous slices from mitral annulus 
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